Tc 99m fanolesomab

Drug Profile

Tc 99m fanolesomab

Alternative Names: Anti-CD15 IgM monoclonal antobody Tc 99m; Fanolesomab-Tc 99m; LeuTech; NeutroSpec; Tc 99m-anti-SSEA-1; Tc 99m-RB5 IgM; Technetium 99m-labeled mouse anti-CD-15 IgM monoclonal antibody

Latest Information Update: 21 Dec 2005

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Palatin Technologies; Wistar Institute
  • Class Heavy metals; Monoclonal antibodies; Monoclonal antibody diagnostics; Radiopharmaceutical diagnostics
  • Mechanism of Action Radionuclide imaging enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Market Withdrawal Infections

Most Recent Events

  • 19 Dec 2005 Withdrawn for Infection diagnosis in USA (IV)
  • 05 Dec 2005 Palatin and Tyco Healthcare communicated to healthcare providers several reports in patients with severe cardiopulmonary co-morbidities who experienced life-threatening or fatal reactions after administration of Tc 99m fanolesomab
  • 31 Aug 2004 Launched for Infection diagnosis in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top